Sera Prognostics (NASDAQ:SERA) CEO Zhenya Lindgardt Sells 20,755 Shares

Posted by Brenda Bartman on Jun 11th, 2026

Sera Prognostics, Inc. (NASDAQ:SERA – Get Free Report) CEO Zhenya Lindgardt sold 20,755 shares of Sera Prognostics stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total transaction of $43,170.40. Following the completion of the transaction, the chief executive officer directly owned 871,999 shares in the company, valued at approximately $1,813,757.92. The trade was a 2.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Stock Performance

Shares of SERA opened at $2.00 on Thursday. Sera Prognostics, Inc. has a twelve month low of $1.43 and a twelve month high of $4.09. The firm’s 50 day moving average price is $2.03 and its two-hundred day moving average price is $2.55. The firm has a market cap of $78.32 million, a P/E ratio of -3.08 and a beta of 0.94.

Sera Prognostics (NASDAQ:SERA – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.07 million. Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. On average, sell-side analysts anticipate that Sera Prognostics, Inc. will post -0.58 earnings per share for the current fiscal year.

Institutional Trading of Sera Prognostics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in Sera Prognostics during the fourth quarter worth about $203,000. Barclays PLC raised its holdings in Sera Prognostics by 267.4% during the fourth quarter. Barclays PLC now owns 36,722 shares of the company’s stock worth $108,000 after acquiring an additional 26,726 shares in the last quarter. Two Sigma Investments LP bought a new stake in Sera Prognostics during the third quarter worth about $97,000. Qube Research & Technologies Ltd bought a new stake in Sera Prognostics during the second quarter worth about $92,000. Finally, Cetera Investment Advisers bought a new stake in Sera Prognostics during the fourth quarter worth about $74,000. Institutional investors own 54.64% of the company’s stock.

Analysts Set New Price Targets

SERA has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Sera Prognostics in a report on Friday, March 27th. Craig Hallum initiated coverage on Sera Prognostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Read Our Latest Report on Sera Prognostics

Sera Prognostics Company Profile

(Get Free Report)

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.